🔴 Neurosense Therapeutics is trading 10.22% down in pre-market after announcing 1-for-20 reverse share split

Neurosense Therapeutics is trading 10.22% down in pre-market at $0.36 after announcing a 1-for-20 reverse share split on September 9, 2026.

• The consolidation reduces outstanding shares from 37,938,036 to approximately 1,896,902.
• Post-split trading begins September 14.
• The sharp pre-market decline reflects investor concern surrounding the company’s share structure and Nasdaq listing pressure.